Insider

Resmed Inc

RMD Health Care · 3 analyses · 3 expectations tracked

Resmed reported $1.4B in revenue (+5.9% YoY), compared with a +7.2% median across covered Health Care peers. Of 3 tracked management expectations, 2 were consistent with later reports and 0 were contradicted. 3 insider sales recorded. Its latest periodic filing added 29 new risk factors. Next scheduled event: Annual meeting on November 18, 2026.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

Deals & ownership

ResMed executives filed reports on stock transactions

Michael J. Farrell, chair and CEO of ResMed, filed a notice of a proposed sale of 4,993 shares on November 9, 2026. On November 11, several company executives and directors conducted stock transactions to cover tax obligations. These reports reflect standard corporate compensation management procedures.

· Resmed Inc
What changed

ResMed grew revenue 8% and returned over $1 billion to shareholders in 2026

ResMed reported that for fiscal year 2026 revenue grew 8% in constant currency, free cash flow exceeded $1.6 billion, and the company returned more than $1 billion to shareholders. It completed the acquisition of Noctrix Health for $340 million, and proceeds from the MatrixCare sale are being used for an accelerated share repurchase (ASR).

· Resmed Inc

Upcoming events

As announced by the companies, read by code from their press releases, 8-Ks and official feeds; each date links its announcement. Companies can change dates. Dividends: common shares only; under T+1 settlement the ex-dividend date is normally the record date. Corporate calendar →

Company history

October 2026

RESMED INC: 12 recorded developments from 1 official source in 2026-10.

  • 2026-10-30: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), quarter 2026-07-01 to 2026-09-30: 1,414,814,000 USD (1.4 billion; 1,415 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,335,582,000 USD (1.3 billion; 1,336 million); change +5.9% Source
  • 2026-10-30: Gross profit (us-gaap:GrossProfit), quarter 2026-07-01 to 2026-09-30: 870,567,000 USD (871 million); same period a year earlier (2025-07-01 to 2025-09-30): 817,664,000 USD (818 million); change +6.5% Source
  • 2026-10-30: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-07-01 to 2026-09-30: 452,984,000 USD (453 million); same period a year earlier (2025-07-01 to 2025-09-30): 446,537,000 USD (447 million); change +1.4% Source
  • 2026-10-30: Net income (us-gaap:NetIncomeLoss), quarter 2026-07-01 to 2026-09-30: 418,413,000 USD (418 million); same period a year earlier (2025-07-01 to 2025-09-30): 348,536,000 USD (349 million); change +20% Source
  • 2026-10-30: Dividends per share (us-gaap:CommonStockDividendsPerShareDeclared), quarter 2026-07-01 to 2026-09-30: 0.66 USD/shares; same period a year earlier (2025-07-01 to 2025-09-30): 0.6 USD/shares; change +10% Source
  • 2026-10-30: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), quarter 2026-07-01 to 2026-09-30: 102,860,000 USD (103 million); same period a year earlier (2025-07-01 to 2025-09-30): 89,479,000 USD (89 million); change +15% Source
  • 2026-10-30: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), quarter 2026-07-01 to 2026-09-30: 422,422,000 USD (422 million); same period a year earlier (2025-07-01 to 2025-09-30): 457,321,000 USD (457 million); change -7.6% Source
  • 2026-10-30: Capital expenditure (us-gaap:PaymentsToAcquirePropertyPlantAndEquipment), quarter 2026-07-01 to 2026-09-30: 48,740,000 USD (49 million); same period a year earlier (2025-07-01 to 2025-09-30): 42,965,000 USD (43 million); change +13.4% Source
  • 2026-10-30: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 1,010,742,000 USD (1 billion; 1,011 million); previous balance (2026-06-30): 1,469,234,000 USD (1.5 billion; 1,469 million); change -31.2% Source
  • 2026-10-30: Total assets (us-gaap:Assets), as of 2026-09-30: 8,211,811,000 USD (8.2 billion; 8,212 million); previous balance (2026-06-30): 8,965,950,000 USD (9 billion; 8,966 million); change -8.4% Source
  • 2026-10-30: Total liabilities (us-gaap:Liabilities), as of 2026-09-30: 2,264,121,000 USD (2.3 billion; 2,264 million); previous balance (2026-06-30): 2,380,557,000 USD (2.4 billion; 2,381 million); change -4.9% Source
  • 2026-10-30: Shareholders' equity (us-gaap:StockholdersEquity), as of 2026-09-30: 5,947,690,000 USD (5.9 billion; 5,948 million); previous balance (2026-06-30): 6,585,393,000 USD (6.6 billion; 6,585 million); change -9.7% Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed October 30, 2026. SEC

LatestEarlierChange
Revenue quarter$1.4B$1.3B+5.9%
Operating income quarter$453M$447M+1.4%
Net income quarter$418M$349M+20.0%
Diluted EPS quarter$2.92$2.37+23.2%
Dividends per share quarter$0.66$0.60+10.0%
Operating cash flow quarter$422M$457M-7.6%
Cash and cash equivalents balance$1B$1.5B-31.2%
Long-term debt balance$250M$399M-37.5%

Next results expected around January 29, 2027 (estimate: the quarter ending about December 30, 2026 plus the 30 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

1.3Q2 '2532.5%1.3Q3 '2533%1.3Q4 '25*33.7%1.3Q1 '2633.4%1.4Q2 '2634.6%1.4Q3 '2634.9%1.5Q4 '26*30.7%1.4Q1 '2732%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Resmed Inc RMD$1.4B+5.9%32.0%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

How expectations played out

2 of 3 expectations checked against later reports

  • 2 confirmed

Mostly AI assessments, provisional; an editor's decision replaces them. Not a rating of the shares.

Checked against later reports

  • Plan to return more than $1.85 billion to stockholders in fiscal year 2027.

    Said October 1, 2026 · Period named: fiscal year 2027 · Source · Our article

    AI assessment, provisional later reports are consistent with it (as of October 29, 2026) · Later article

  • Expect to repurchase approximately $1.5 billion of ResMed shares over fiscal 2027, inclusive of the accelerated share repurchase.

    Said October 1, 2026 · Period named: fiscal 2027 · Source · Our article

    AI assessment, provisional later reports are consistent with it (as of October 29, 2026) · Later article

Open

  • ResMed plans to continue building its core sleep and breathing health businesses by extending the reach of its digital health ecosystem and connecting more people worldwide with home-based treatment.

    Said October 29, 2026 · Period named: rest of fiscal year 2027 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Changes in risk factors

The 10-Q filed October 30, 2026 compared with the 10-Q filed May 1, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC

Added (29)

  • | 191,038 | | $ | 764 | | $ | 2,190,614 | | (46,798) | | $ | (2,778,591) | | $ | 7,255,121 | | $ | (82,515) | | $ | 6,585,393
  • | 191,081 | | $ | 764 | | $ | 2,133,418 | | (50,442) | | $ | (3,633,335) | | $ | 7,578,580 | | $ | (131,737) | | $ | 5,947,690
  • | 190,311 | | $ | 761 | | $ | 2,033,599 | | (43,926) | | $ | (2,073,292) | | $ | 6,081,490 | | $ | (74,699) | | $ | 5,967,859

Dropped (59)

  • Other intangible assets, net (note 3) | 425,185 | | | 464,861
  • | $ | 1,260,516 | | | $ | 1,130,575 | | | $ | 3,685,900 | | | $ | 3,323,905
  • Net revenue | 1,431,406 | | | 1,291,736 | | | 4,189,796 | | | 3,798,334

Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
August 17, 2026Change of auditor (8-K item 4.01)8-K
August 17, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 17, 2026De Witte JanPlanned sale 10b5-1 plan429—$101,673SEC
November 9, 2026Michael J. FarrellSale 10b5-1 plan notice filed4,993$235.35$1,175,089SEC
October 23, 2026Michael J RiderSale 10b5-1 plan notice filed400$255.00$102,000SEC
October 7, 2026Michael J. FarrellSale 10b5-1 plan notice filed4,991$226.33$1,129,637SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock11,954,239$2,643,082,249-2.9%Q3 2026
State Street6,519,249$1,441,405,954-2.4%Q3 2026
Geode Capital Management4,420,200$973,889,075+1.6%Q3 2026
Norges Bank (Norway's sovereign fund)664,714$129,539,464—Q2 2026
Citadel Advisors527,861$116,710,068+3.9%Q3 2026
Two Sigma Investments295,657$65,369,763-28.1%Q3 2026
Fidelity (FMR)251,972$55,711,168+16.3%Q3 2026
Millennium Management100,045$22,119,950-51.1%Q3 2026
Renaissance Technologies93,920$20,765,712+5,697.5%Q3 2026
Wellington Management93,564$20,687,001+15.2%Q3 2026
Bridgewater Associates14,487$3,203,076-78.5%Q3 2026
D. E. Shaw & Co.5,819$1,286,581-4.9%Q3 2026
T. Rowe Price462,455$102,250+24.4%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.